SCHEMBL29520830

SCHEMBL29520830

Fc1cc2[nH]ncc2cc1C1CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 3/20 0.50
▸ MET P08581 2/20 0.44
▸ CHEK1 O14757 1/20 0.43
▸ ROCK2 O75116 3/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ FGFR1 P11362 2/20 0.40
▸ FGFR2 P21802 2/20 0.40
▸ KDM4E B2RXH2 3/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ MAPT P10636 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ APAF1 O14727 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ METAP2 P50579 3/20 0.38
▸ NOS1 P29475 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24364954 0.77 MET (0.39) TRPA1METCHEK1ROCK2KDM4E
SCHEMBL14738406 0.77 CHEK1 (0.56) TRPA1CHEK1ROCK2GSK3BFGFR1
SCHEMBL28492362 0.76 TRPA1 (0.44) TRPA1CHEK1ROCK2JAK2GSK3B
SCHEMBL29081399 0.75 MET (0.40) TRPA1METCHEK1ROCK2FGFR1
SCHEMBL31145119 0.75 MET (0.40) TRPA1METCHEK1ROCK2FGFR1
SCHEMBL13692758 0.72 NOS1 (0.52) TRPA1CHEK1ROCK2GSK3BFGFR1
SCHEMBL12435218 0.71 CHEK1 (0.48) TRPA1METCHEK1FGFR1FGFR2
SCHEMBL828690 0.71 AXL (0.56) TRPA1CHEK1ROCK2GSK3BFGFR1
SCHEMBL1273798 0.71 CHEK1 (0.70) TRPA1METCHEK1ROCK2GSK3B
SCHEMBL31633137 0.71 FGFR1 (0.60) TRPA1CHEK1ROCK2FGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649255-B2 Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same 1ST Biotherapeutics, Inc. (KR) 2023-05-16 — — US disclosed
US-20220098193-A1 INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME 1ST Biotherapeutics, Inc. 2022-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649255-B2 Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same IP6K1, HIPK1, IP6K3 TRPA1 4861/4885MET 1356/4885CHEK1 179/4885
US-20220098193-A1 INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME IP6K1, HIPK1, IP6K3 TRPA1 4861/4885MET 1356/4885CHEK1 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback